Vasoactive mediators (VEGF and TNF-α) in patients with malignant and tuberculous pleural effusions

Respirology

Volumn 9, Issue 1, 2004, Pages 81-86

  Hamed, Enas A ^a,b   El Noweihi, Amira M ^a   Mohamed, Ashraf Z ^a   Mahmoud, Azza ^a  

^a Faculty of Medicine   (Egypt)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

Exudates; Malignancy; Pleural fluid; Transudates; Tuberculosis; Tumour necrosis factor alpha; Vascular endothelial growth factor

Indexed keywords

NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; ASCITES; BLOOD VESSEL PERMEABILITY; CANCER PATIENT; CLINICAL ARTICLE; COLORIMETRY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PATHOGENESIS; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; TUBERCULOSIS; VASODILATATION;

ADULT; COLORIMETRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NITRIC OXIDE; PLEURAL EFFUSION, MALIGNANT; TUBERCULOSIS, PLEURAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2442507671     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2003.00529.x     Document Type: Article

References (30)

1. Antony VB, Godbey SW, Kunkel SL et al. Recruitment of inflammatory cells to the pleural space: chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J. Immunol. 1993; 151: 7216-23.
2. Yano S, Shinohara H, Kuniyasu H. Formation of pleural effusion by human lung adenocarcinoma directly correlates with expression of VEGF/VPF. Proc. Am. Assoc. Cancer Res. 1999; 40: 227a.
3. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13: 9-22.
4. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54: 707-10.
5. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr. Opin. Pulm. Med. 2002; 8: 294-301.
6. Boussat S, Eddahibi S, Coste A et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000; 279: L371-L378.
7. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl Acad. Sci. USA 1998; 95: 15 809-14.
8. Hoheisel G, Izbicki G, Roth M et al. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy. Respiration 1998; 65: 183-6.
9. Ryuto M, Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 1996; 271: 28 220-8.
10. Worrall NK, Chang K, Le Jeune WS et al. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms. Am. J. Physiol. 1997; 273: H2565-H2574.
11. Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin. Exp. Immunol. 1998; 113: 147-56.
12. Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 1999; 6: 23-44.
13. Light RW, MacGregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann. Intern. Med. 1972; 77: 507-13.
14. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 1988; 141: 2407-12.
15. Motulsky HJ. Analysing Data with Graphpad Prism. GraphPad Software Inc, San Diego, CA 1999, 207-21.
16. Brown LF, Detmar M, Claffey K et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997; 79: 233-69.
17. Odeh M, Sabo E, Srugo I, Oliven A. Tumour necrosis factor alpha in the diagnostic assessment of pleural effusion. QJM 2000; 93: 819-24.
18. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol. Immunother. 1999; 48: 396-400.
19. Soderblom T, Nyberg P, Teppo AM, Klockars M, Riska H, Pettersson T. Pleural fluid interferon-γ and tumour necrosis factor-α in tuberculous and rheumatoid pleurisy. Eur. Respir. J. 1996; 9: 1652-5.
20. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazunder A, Modlin RL. Local production of tumor necrosis factor alpha and IFN-ω in tuberculous pleuritis. J. Immunol. 1990; 145: 149-54.
21. Kim YC, Park KO, Bom HS et al. Combining ADA, protein and IFN-γ best allows discrimination between tuberculous and malignant pleural effusion. Korean J. Intern. Med. 1997; 12: 225-31.
22. Abraham D, Hofbauer R, Schafer R et al. Selective down-regulation of VEGF-A (165), VEGF-R (1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ. Res. 2000; 87: 644-7.
23. Chin BS, Chung NA, Gibbs CR, Blann AD, Lip GY. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am. J. Cardiol. 2002; 90: 1258-60.
24. Fang ZY, Marwick TH. Vascular dysfunction and heart failure: epiphenomenon or etiologic agent? Am. Heart J. 2002; 143: 383-90.
25. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 1993; 265: H586-H592.
26. Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999; 85: 178-87.
27. Momi H, Matsuyama W, Inoue K et al. Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir. Med. 2002; 96: 817-22.
28. Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE, Antony VB. Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001; 281: L119-L125.
29. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 1995; 108: 2369-79.
30. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest. Ophthalmol. Vis. Sci. 1999; 40: 689-96.